Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 4, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	5,407	2,224	1,563	1,606	818	276
Market Cap Growth	74.83%	42.30%	-2.70%	96.45%	196.48%	175.69%
Enterprise Value	5,345	2,144	1,482	1,572	801	270
PE Ratio	166.61	626.21	-	-	-	-
PS Ratio	9.65	6.49	14.37	290.85	203.32	112.65
PB Ratio	15.43	21.91	28.75	1023.78	13.41	5.60
P/TBV Ratio	1387.98	83.14	109.40	-	53.46	13.95
P/FCF Ratio	218.97	229.72	-	-	619.12	-
P/OCF Ratio	163.04	136.63	-	-	540.78	-
EV/Sales Ratio	12.41	6.26	13.62	284.54	199.24	110.26
EV/EBITDA Ratio	109.53	55.00	-	-	-	-
EV/EBIT Ratio	118.94	60.60	-	-	-	-
EV/FCF Ratio	216.45	221.37	-	-	606.68	-
Debt / Equity Ratio	0.05	0.12	0.13	1.18	0.03	0.03
Debt / EBITDA Ratio	0.30	0.30	-	-	-	-
Debt / FCF Ratio	0.58	1.23	-	-	1.29	-
Asset Turnover	1.22	1.54	0.88	0.06	0.04	0.04
Inventory Turnover	11.07	14.59	10.92	1.25	3.45	4.29
Quick Ratio	0.81	1.24	1.90	1.13	4.62	5.42
Current Ratio	0.99	1.43	2.02	1.25	4.69	5.52
Return on Equity (ROE)	20.49%	4.55%	-253.34%	-198.36%	-60.21%	-45.32%
Return on Assets (ROA)	7.97%	9.92%	-25.37%	-37.95%	-23.64%	-28.06%
Return on Capital (ROIC)	16.34%	25.26%	-97.35%	-118.20%	-40.13%	-39.67%
Earnings Yield	0.61%	0.16%	-4.53%	-3.64%	-4.23%	-7.10%
FCF Yield	0.46%	0.44%	-3.09%	-2.75%	0.16%	-6.05%
Buyback Yield / Dilution	-5.90%	-4.21%	-10.08%	-9.69%	-10.21%	-15.49%
Total Shareholder Return	-5.90%	-4.21%	-10.08%	-9.69%	-10.21%	-15.49%

Source: S&P Capital IQ. Standard template. Financial Sources.